Glycopyrrolate/formoterol fumarate vs Tiotropium bromide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere

Marketed by AstraZeneca

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Weak signal

NCT03324607 · Phase 2/3 · completed

The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.

Reported efficacy

Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)

Result source: NCT03324607

Tiotropium bromide

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT02172287 · Phase 3 · completed

This 6-month trial randomly assigned 623 patients with COPD to tiotropium, salmeterol or placebo, with double-blind, double-dummy treatment. The two primary measures were trough FEV1 and the Transition Dyspnea Index (TDI). Tiotropium raised trough FEV1 by 0.14 L more than placebo, more than salmeterol did (0.09 L; p<0.01 for tiotropium against salmeterol), and improved the TDI focal score by 1.02 units against placebo (p=0.01). Both primary measures favoured tiotropium, so the result is met. The figures come from the peer-reviewed paper in Chest (2002).

Reported efficacy

Change from baseline in trough Forced expiratory volume in one second (FEV1) response (baseline, up to day 169); Change from baseline in Mahler Transitional Dyspnoea Index (TDI) (baseline, up to day 169): Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. (met)

Result source: NCT02172287

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlycopyrrolate/​formoterol fumarateTiotropium bromide
Moderate or severe exacerbations, annualised rate—Not reported0.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986
Trough FEV1, change—Not reported0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788
SGRQ total, change—Not reported-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470
TDI focal score—Not reported—Not posted · NCT02172287

Moderate or severe exacerbations, annualised rate

Glycopyrrolate/​formoterol fumarate
—Not reported
Tiotropium bromide
0.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986

Trough FEV1, change

Glycopyrrolate/​formoterol fumarate
—Not reported
Tiotropium bromide
0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788

SGRQ total, change

Glycopyrrolate/​formoterol fumarate
—Not reported
Tiotropium bromide
-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470

TDI focal score

Glycopyrrolate/​formoterol fumarate
—Not reported
Tiotropium bromide
—Not posted · NCT02172287
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Glycopyrrolate/formoterol fumarate: 3 of 5 rows · Tiotropium bromide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGlycopyrrolate/​formoterol fumarateTiotropium bromide
FEV1
absolute change · L
No placebo or comparator arm
0.219 L @ 2wk*a,b,c,d
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 219 mL as posted
1.651 L @ 4wk5 mcge,a,b,c,d
NCT02683668 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.58 L @ 4wk18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
1.575 L @ 4wk18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
Dropout rate
0%f
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
10.3%50/250 µg BIDg
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
15%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
33.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT00523991 · Phase 4 · registry result, not featured evidence
7.9%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
13.3%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
0%18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
23.2%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23.4%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
13.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
16.1%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
6.3%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—f
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
6.4%50/250 µg BIDg
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
10.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT00523991 · Phase 4 · registry result, not featured evidence
2.4%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
10.6%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
11.1%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
10.5%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
3.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.2%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.1%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
1.1%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
0%f
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
12.5%
NCT03081156 · Phase 4 · registry result, not featured evidence
—50/250 µg BIDg
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
5.9%50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
8.8%50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.7%18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
37.5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
25.6%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
0%50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
3.8%50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
4.2%
NCT00523991 · Phase 4 · registry result, not featured evidence
3%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
0%
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
7.3%400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
32.9%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.9%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.8%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
0%150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
0%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
2%5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
3.7%5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
1.8%10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
0%tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
2.7%tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.4%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs—
50/250 µg BIDg
nasopharyngitis 18.4%
dysphonia 13.2%
bronchitis 5.1%
NCT01762800 · Phase 4 · registry result, not featured evidence
show 27 more results
50/250 µg BID + 18 µg QD
nasopharyngitis 20.6%
bronchitis 10.3%
dysphonia 8.8%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18 µg QD + 50/250 µg BID
nasopharyngitis 26.7%
dysphonia 8%
bronchitis 6.7%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18μg
chronic obstructive pulmonary disease 37.5% (placebo 43.6%)
bronchitis 7.5% (placebo 5.1%)
insomnia 5% (placebo 5.1%)
NCT01663987 · Phase 4 · registry result, not featured evidence
18 μg
chronic obstructive pulmonary disease 25.6% (placebo 15.4%)
contusion 7.7% (placebo 0%)
oedema peripheral 7.7% (placebo 0%)
NCT01662986 · Phase 4 · registry result, not featured evidence
50/250 µg BID
dysphonia 5.9%
constipation 2%
dry mouth 2%
NCT01751113 · Phase 4 · registry result, not featured evidence
50/250 µg BID + 18 µg QD
dysphonia 9.6%
nasopharyngitis 5.8%
arthralgia 3.8%
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
nasophayngitis 6.7% (placebo 5%)
chronic obstructive pulmonary disease 4.6% (placebo 9.6%)
NCT00523991 · Phase 4 · registry result, not featured evidence
chronic obstructive pulmonary disease 6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary 15.6%
nasopharyngitis 11.5%
headache 5.1%
NCT02796677 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 32.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
18 mcg
chronic obstructive pulmonary disease 33.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
2.5 mcg
chronic obstructive pulmonary disease 33.8%
NCT01126437 · Phase 3 · registry result, not featured evidence
10 μg
cough 3.3% (placebo 0%)
headache 3.3% (placebo 3%)
urinary tract infection 3.3% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
40 μg
dry mouth 12.9% (placebo 0%)
dizziness 3.2% (placebo 6.1%)
back pain 0% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
20 μg
back pain 6.3% (placebo 3%)
headache 6.3% (placebo 3%)
cough 3.1% (placebo 0%)
NCT03118765 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 9.3% (placebo 4.1%)
dyspnoea 2% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
18 mcg
nasopharyngitis 4.8% (placebo 4.1%)
dyspnoea 2.1% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
2.5 mcg
dyspnoea 1.4% (placebo 9.5%)
nasopharyngitis 1.4% (placebo 4.1%)
NCT01222533 · Phase 2 · registry result, not featured evidence
1.25 mcg
nasopharyngitis 6.1% (placebo 4.1%)
dyspnoea 3.4% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 10.2%
chronic obstructive pulmonary disease 5.6%
NCT01040403 · Phase 2 · registry result, not featured evidence
10 mcg
nasopharyngitis 6.4%
chronic obstructive pulmonary disease 5.5%
NCT01040403 · Phase 2 · registry result, not featured evidence
tiotropium 5 mcg + olodaterol 10 mcg
chronic obstructive pulmonary disease 3.6%
nasopharyngitis 1.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 5 mcg + olodaterol 5 mcg
chronic obstructive pulmonary disease 7.3%
nasopharyngitis 2.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 10 mcg
nasopharyngitis 3.6%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 5 mcg
nasopharyngitis 7.1%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 10 mcg
nasopharyngitis 7.3%
chronic obstructive pulmonary disease 6.4%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 5 mcg
nasopharyngitis 11%
chronic obstructive pulmonary disease 3.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2/3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 4 weeks versus 2 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for 1 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Glycopyrrolate/formoterol fumarate

FVC 0.342 L @ 2wk
absolute change · L
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 342 mL as posted
Six Minute Walk 16.2 m @ 2wk
absolute change · m
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
SGRQ Total -1.2 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
RPD -0.75 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
Exercise Endurance Time Seconds 382.5 vs 328 placebo seconds
absolute value · seconds
NCT03081156 · Phase 4 · registry result, not featured evidence

Tiotropium bromide

Time to First Exacerbation 0.1 vs 0.33 TIO months50/250 µg BID
time to event · months
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 3 days as posted
show 5 more results
0.16 vs 0.33 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 5 days as posted
0 vs 0 TIO months*50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 0 days as posted
0 vs 0 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 0 days as posted
0.07 vs 0.33 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 2 days as posted
0.03 vs 0 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 1 days as posted
EXACT Total 27.83 vs 28.88 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.92 vs 28.88 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
38.26 vs 28.88 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.35 vs 28.8 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
37.58 vs 28.8 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.87 vs 28.8 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.63 vs 28.4 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.16 vs 28.4 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.57 vs 28.4 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.33 vs 28.93 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
35.92 vs 28.93 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.79 vs 28.93 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.98 vs 28.66 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
34.92 vs 28.66 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
34.03 vs 28.66 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.5 vs 28.8 TIO score @ 24wk50/250 µg BID
absolute value · score
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
32.72 vs 28.8 TIO score @ 24wk50/250 µg BID + 18 µg QD
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.67 vs 28.8 TIO score @ 24wk18 µg QD + 50/250 µg BID
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.76 vs 7.18 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
12.39 vs 7.18 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
13.23 vs 7.18 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.75 vs 6.99 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.86 vs 6.99 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.11 vs 6.99 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.69 vs 6.7 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.79 vs 6.7 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.3 vs 6.7 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.23 vs 6.82 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.66 vs 6.82 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.26 vs 6.82 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.33 vs 6.85 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
10.8 vs 6.85 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
9.89 vs 6.85 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination

+ 115 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrrolate/formoterol fumarate's landscape · Tiotropium bromide's landscape